Plain-English translation of NCT05521984 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a medication called to see if it is safe and helpful when added to standard chemotherapy for children and young adults with brain tumors or solid tumors that have come back or stopped responding to earlier treatments. is normally used to treat diabetes, but researchers believe it may help fight cancer by changing how tumor cells use energy. The main goal is to make sure the medication is safe and well-tolerated in this young patient population.
Children and young adults with recurrent or treatment-resistant cancers have limited options, and standard chemotherapy alone is not always enough. This trial exists to explore whether this medication, which works through a different mechanism than traditional cancer drugs, could boost the effectiveness of standard chemotherapy and improve outcomes for these patients.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth once daily for 12 weeks at the same time you receive your standard chemotherapy. Depending on your age, you may start at a lower dose that increases after two weeks. You will need regular blood tests and check-ins with the study team, including an endocrinologist (a doctor who specializes in metabolism and hormones), to monitor how well you tolerate the medication and how you respond to the combined treatment.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
United States